Stability of trastuzumab during nanomedicine formulation using SEC-HPLC coupled with polyacrylamide gel electrophoresis

References

• Arakawa T, Ejima D, Li T, Philo JS. 2010. The critical role of mobile phase composition in size exclusion chromatography of protein pharmaceuticals. J Pharm Sci. 99(4):1674–1692.
   PubMed Web of Science ®Google Scholar
• Bana AA, Mehta P, Ramnani KA. 2022. Physical instabilities of therapeutic monoclonal antibodies: a critical review. Curr Drug Discov Technol. 19(6):e240622206367.
   PubMedGoogle Scholar
• Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V. 2020. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 109(1):169–190.
   PubMed Web of Science ®Google Scholar
• Bekard IB, Asimakis P, Bertolini J, Dunstan DE. 2011. The effects of shear flow on protein structure and function. Biopolymers. 95(11):733–745.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Herceptin Adjuvant (HERA) Trial Study Team, et al. 2017. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 389(10075):1195–1205., al et.
   PubMed Web of Science ®Google Scholar
• Chan C, Seki JT, Kwong R, Reilly RM. 2020. The pharmaceutical stability of trastuzumab after short-term storage at room temperature assessed by analytical techniques and tumour imaging by microSPECT/CT. Int J Pharm. 588:229786.
   Google Scholar
• Den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W. 2011. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res. 28(4):920–933.
   PubMed Web of Science ®Google Scholar
• Ferraro E, Drago JZ, Modi S. 2021. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res. 23(1):1–11.
   PubMed Web of Science ®Google Scholar
• Gao Y, Tang M, Leung E, Svirskis D, Shelling A, Wu Z. 2020. Dual or multiple drug loaded nanoparticles to target breast cancer stem cells. RSC Adv. 10(32):19089–19105.
   PubMed Web of Science ®Google Scholar
• Goyon A, Fekete S, Beck A, Veuthey JL, Guillarme D. 2018. Unraveling the mysteries of modern size exclusion chromatography - the way to achieve confident characterization of therapeutic proteins. J Chromatogr B Analyt Technol Biomed Life Sci. 1092:368–378.
   PubMed Web of Science ®Google Scholar
• FDA. 1998. Herceptin (Trastuzumab) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.
   Google Scholar
• Hong P, Koza S, Bouvier ESP. 2012. Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates. J Liq Chromatogr Relat Technol. 35(20):2923–2950.
   PubMed Web of Science ®Google Scholar
• Huang X, Caddell R, Yu B, Xu S, Theobald B, Lee J, Lee RJ. 2010. Ultrasound-enhanced Microfluidic Synthesis of Liposomes. Anticancer Res. 30(2):463–466.
   PubMed Web of Science ®Google Scholar
• Hudis CA. 2007. Trastuzumab – Mechanism of action and use in clinical practice. N Engl J Med. 357(1):39–51.
   PubMed Web of Science ®Google Scholar
• Kaiser J, Kramer I. 2011. Physiochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags. Int J Pharm Compd. 15(6):515–520.
   Google Scholar
• Kirley TL, Norman AB. 2018. Unfolding of IgG domains detected by non-reducing SDS-PAGE. Biochem Biophys Res Commun. 503(2):944–949.
   PubMed Web of Science ®Google Scholar
• Kulhari H, Pooja D, Rompicharla SVK, Sistla R, Adams DJ. 2015. Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand. Med Res Rev. 35(4):849–876.
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Chumsae C, Newby-Kew A. 2007. Characterization of lower molecular weight artifact bands of recombinant monoclonal IgG1 antibodies on non-reducing SDS-PAGE. Biotechnol Lett. 29(11):1611–1622.
   PubMed Web of Science ®Google Scholar
• Ma H, Ó'Fágáin C, O'Kennedy R. 2020. Antibody stability: a key to preformance – Analysis, influences and improvement. Biochimie. 177:213–225.
   PubMed Web of Science ®Google Scholar
• Maadi H, Nami B, Tong J, Li G, Wang Z. 2018. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer. 18(1):238.
   PubMedGoogle Scholar
• Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 98(9):2909–2934.
   PubMed Web of Science ®Google Scholar
• Mandó P, Rivero SG, Rizzo MM, Pinkasz M, Levy EM. 2021. Targeting ADCC: a different approach to HER2 breast cancer in the immunotherapy era. Breast. 60:15–25.
   PubMed Web of Science ®Google Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, Sawant KK, Ramachandra Murthy RS. 2011. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release. 150(1):2–22.
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. 2019. Advances in HER2-Targeted Therapy: novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res. 25(7):2033–2041.
   PubMed Web of Science ®Google Scholar
• Meza-Junco J, Au HJ, Sawyer MB. 2009. Trastuzumab for gastric cancer. Expert Opin Biol Ther. 9(12):1543–1551.
   PubMed Web of Science ®Google Scholar
• Mohamed HE, Mohamed AA, Al-Ghobashy MA, Fathalla FA, Abbas SS. 2018. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. J Pharm Biomed Anal. 150:268–277.
   PubMed Web of Science ®Google Scholar
• Nalenz H, Kopf E, Dietel E. 2018. Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags. Int J Pharm Compd. 22(5):417–423.
   PubMedGoogle Scholar
• Nieto C, Vega MA, Del Valle EMM. 2020. Trastuzumab: more than a guide in her2-positive cancer nanomedicine. Nanomaterials. 10(9):1–20.
   Web of Science ®Google Scholar
• Niza E, Noblejas-López MDM, Bravo I, Nieto-Jiménez C, Castro-Osma JA, Canales-Vázquez J, Lara-Sanchez A, Moya EMG, Burgos M, Ocaña A, et al. 2019. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastasic breast cancer. Nanomater 9(12):1793.
   Web of Science ®Google Scholar
• Pabari RM, Ryan B, Mccarthy C, Ramtoola Z. 2011. Effect of Microencapsulation Shear Stress on the Structural Integrity and Biological Activity of a Model Monoclonal Antibody, Trastuzumab. Pharmaceutics. 3(3):510–524.
   PubMedGoogle Scholar
• Patapoff TW, Esue O. 2009. Polysorbate 20 prevents the precipitation of a monoclonal antibody during shear. Pharm Dev Technol. 14(6):659–664.
   PubMed Web of Science ®Google Scholar
• Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A. 2013. Long-term physico-chemical stability of diluted trastuzumab. Int J Pharm. 448(1):101–104.
   PubMed Web of Science ®Google Scholar
• Pérez LM, Rodríguez Taño AdlC, Martín Márquez LR, Gómez Pérez JA, Garay AV, Santana RB. 2019. Conformational characterization of a novel anti-HER2 candidate antibody. PLoS One. 14(5):e0215442.
   PubMed Web of Science ®Google Scholar
• Porterfield JZ, Alotnick A. 2010. A simple and general method for determing the protein and nucleic acid content of viruses by UV absorbance. Virology. 407(2):281–288.
   PubMed Web of Science ®Google Scholar
• Pucci F, Dhanani M, Dehouck Y, Rooman M. 2014. Protein Thermostability Prediction within Homologous Families Using Temperature-Dependent Statistical Potentials. PLoS One. 9(3):e91659.
   PubMed Web of Science ®Google Scholar
• Rodallec A, Brunel J-M, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, et al. 2018. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. Int J Nanomedicine. 13:3451–3465.
   PubMed Web of Science ®Google Scholar
• Schlam I, Swain SM. 2021. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. Breast Cancer. 7(1):56.
   PubMed Web of Science ®Google Scholar
• Sert F, Hız D, Gülmez M, Ezgi Cankurtaran S, Irmak Kayalan C, Kurt H, Yüce M. 2022. Temperature and pH-dependent behaviors of mAb drugs: a case study for trastuzumab. Sci Pharm. 90(:21.
   Web of Science ®Google Scholar
• Singh S, Bandi S, Jones D, Mallela K. 2017. Effect of polysorbate 20 and polysorbate 80 on the higher-order structure of a monoclonal antibody and its fab and Fc fragments probed using 2D nuclear magnetic resonance spectroscopy. J Pharm Sci. 106(12):3486–3498.
   PubMed Web of Science ®Google Scholar
• Sundaram Palaniswamy M. 2016. Quantitation of mAb and ADC aggregation using SEC and an aqueous mobile phase.
   Google Scholar
• Thomas CR, Geer D. 2011. Effects of shear on proteins in solution. Biotechnol Lett. 33(3):443–456.
   PubMed Web of Science ®Google Scholar
• Thorat AA, Munjal B, Geders TW, Suryanarayanan R. 2020. Freezing-induced protein aggregation - Role of pH shift and potential mitigation strategies. J Control Release. 323:591–599.
   PubMed Web of Science ®Google Scholar
• EMA 2005. Validation of analytical procedures: text and methodology Q2(R1) In: International conference on harmonisation of technical requirements for registration of pharmaceuticals for human USE. https://database.ich.org/sites/default/files/Q2%28R1%29 Guideline.pdf
   Google Scholar
• Wang W, Nema S, Teagarden D. 2010. Protein aggregation—Pathways and influencing factors. Int J Pharm. 390(2):89–99.
   PubMed Web of Science ®Google Scholar
• Wu Z, Medlicott NJ, Razzak M, Tucker IG. 2005. Development and optimization of a rapid HPLC method for analysis of ricobendazole and albendazole sulfone in sheep plasma. J Pharm Biomed Anal. 39(1-2):225–232.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang G, Falconer JR, Baguley BC, Shaw JP, Liu J, Xu H, See E, Sun J, Aa J, et al. 2015. Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug. Pharm Res. 32(4):1451–1461.
   PubMed Web of Science ®Google Scholar